Aug 6, 2024
C. Scott Franklin- Amount
- $15,001 to $50,000
- Filed
- Aug 20, 2024
Congress ticker disclosure profile
As of August 1 at 7:10 PM EDT
Public STOCK Act rows mentioning
A factual page for public Congressional disclosures that reference DGRO. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.
90d rows
0
Feed lifetime
10
Member filers
3
Disclosed ranges
$41K
Most active member desks
9 buys vs 1 sells
Latest trade Aug 6, 2024
Aug 6, 2024
C. Scott FranklinSep 30, 2022
Kevin HernSep 30, 2021
Kevin HernJul 1, 2021
Kevin HernDec 17, 2020
K. Michael ConawayNov 30, 2020
K. Michael ConawayAug 10, 2020
K. Michael ConawayApr 22, 2020
K. Michael ConawayApr 6, 2020
K. Michael ConawayOct 15, 2019
Kevin Hern| Date | Member | Action | Amount | Filed | Receipt |
|---|---|---|---|---|---|
| Aug 6, 2024 | C. Scott Franklin | Sell | $15,001 to $50,000 | Aug 20, 2024 | Open card |
| Sep 30, 2022 | Kevin Hern | Buy | $1,001 to $15,000 | Oct 10, 2022 | Open card |
| Sep 30, 2021 | Kevin Hern | Buy | Receipt pending ingestion | Oct 7, 2021 | Open card |
| Jul 1, 2021 | Kevin Hern | Buy | Receipt pending ingestion | Sep 15, 2021 | Receipt pending ingestion |
| Dec 17, 2020 | K. Michael Conaway | Buy | Receipt pending ingestion | Jan 22, 2021 | Open card |
| Nov 30, 2020 | K. Michael Conaway | Buy | Receipt pending ingestion | Dec 15, 2020 | Open card |
| Aug 10, 2020 | K. Michael Conaway | Buy | Receipt pending ingestion | Sep 8, 2020 | Open card |
| Apr 22, 2020 | K. Michael Conaway | Buy | Receipt pending ingestion | May 4, 2020 | Open card |
| Apr 6, 2020 | K. Michael Conaway | Buy | Receipt pending ingestion | May 4, 2020 | Open card |
| Oct 15, 2019 | Kevin Hern | Buy | Receipt pending ingestion | Nov 14, 2019 | Open card |
Source creed
This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 2 of 10 filed rows include disclosed amount ranges (20%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.
Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.